Clinical Trial Update: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for catumaxomab in gastric adenocarcinoma with peritoneal carcinomatosis has completed recruitment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma with Peritoneal Carcinomatosis
• Siewert Type Ii Adenocarcinoma of Esophagogastric Junction with Peritoneal Carcinomatosis
• Siewert Type Iii Adenocarcinoma of Esophagogastric Junction with Peritoneal Carcinomatosis

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Phase 2 | Status: COMPLETED